Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2020 - 2025)

Autolus Therapeutics (AUTL) has reported Total Non-Current Liabilities for 6 consecutive years, with $410.5 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 15.63% year-over-year to $410.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $410.5 million (up 15.63% YoY) and the FY2025 annual result came in at $410.5 million, up 15.63% from the prior year.
• Total Non-Current Liabilities advanced to $410.5 million in Q4 2025 per AUTL's latest filing, from $396.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for AUTL reached as high as $410.5 million in Q4 2025 and fell as low as $92.1 million in Q4 2021.
• A 5-year average of $258.0 million and a median of $263.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities climbed 9.39% — and 2023, when it jumped 123.01%.
• Year by year, Total Non-Current Liabilities stood at $92.1 million in 2021, then surged by 107.88% to $191.5 million in 2022, then surged by 37.64% to $263.6 million in 2023, then surged by 34.69% to $355.0 million in 2024, then increased by 15.63% to $410.5 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $410.5 million, $396.0 million, and $374.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.